METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) explained in plain language.

Never miss a new study

Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) trials appear

Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 3 Not yet recruiting 1 Not yet finished but already full! 1 Completed 1

First human tests begin for targeted fatty liver disease drug

Disease control Ongoing

This is an early-stage study to check the safety and side effects of a new drug called LY3849891 in people with fatty liver disease (MASLD) who have a specific genetic marker (PNPLA3 I148M). About 176 participants will receive injections of the drug, and researchers will use bloo…

Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control

Last updated Mar 27, 2026 12:39 UTC

METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) trials appear

First human tests begin for targeted fatty liver disease drug